Sumitomo Chemical India Limited delivered its highest-ever profitability in FY 2025-26, navigating one of the most challenging years the Indian agrochemical industry has witnessed. Despite prolonged and excessive monsoon rainfall through the peak Kharif window, subdued Rabi recovery, regulatory constraints on biostimulants, and geopolitical uncertainty, the Company posted a Profit After Tax of ₹543 crore — a growth of more than 7% year-on-year. Revenue from operations grew 3% to ₹3,238 crore, while the core agrochemical business expanded 5% to 6% on an adjusted basis, almost entirely volume-led. The balance sheet remained essentially debt-free, with net worth growing 17% to ₹3,394 crore, funded entirely through retained earnings.

Financial Performance

The Company's standalone financial results for FY 2025-26 reflect a strong improvement across key profitability metrics. The following table summarises the headline financial performance:

The Board has recommended a dividend of ₹1.30 (13%) per equity share on 499,145,736 shares of ₹10 each, aggregating ₹648.89 million. The record date for dividend eligibility has been fixed as Friday, 17 July 2026, with payment on or after Monday, 3 August 2026.

Segment and Portfolio Performance

Insecticides remained the largest revenue contributor at 41% of total sales, while herbicides were the standout performer, growing 19% on the strength of soybean herbicide flumioxazin, newly launched rice herbicide Lentigo, and flagship glyphosate brand Mera 71. Metal phosphides grew 11%. The Company launched seven products during the year, including patented proprietary technologies Excalia Max and Lentigo from its parent's portfolio. Branded formulations now account for 81% of domestic sales, and the specialty portfolio stands at close to 30% of domestic revenues. Biologicals contribute 8% to 10% of revenue, already above the industry average.

Strategic Developments and Manufacturing Expansion

India has been elevated by parent Sumitomo Chemical Company (SCC), Japan, to the same strategic tier as Japan, Brazil, North America, and Europe for the early-stage introduction of new molecules from the global discovery pipeline. Two such molecules have already been received for trials in Indian conditions ahead of their global launch. The Company is also jointly exploring high-purity chemicals for the semiconductor industry in India. Manufacturing expansion is progressing at Bhavnagar, Tarapur, and Dahej; the first project of ₹150 crore at Dahej is on track towards commercialisation. The Company also resumed distribution of animal nutrition products in response to customer needs and agreed a calibrated royalty arrangement for a select group of products. During FY 2025-26, the Company spent ₹12.40 crore on CSR initiatives, benefitting over 1.49 lakh community members across Maharashtra, Gujarat, West Bengal, and other parts of India.

Leadership Transition and AGM Details

Sumitomo Chemical India has scheduled its Twenty-Sixth Annual General Meeting for Monday, 27 July 2026, at 02:30 P.M. via Video Conferencing. The meeting seeks shareholder approval for the audited financial statements for the year ended 31 March 2026 and a significant leadership transition. Dr Suresh Ramachandran, Deputy Managing Director, is proposed to be promoted to Managing Director effective 1 September 2026, while Mr Chetan Shah, the outgoing Managing Director, is proposed to be appointed as Non-Executive Non-Independent Director from the same date. The Board will thereafter consider Mr Chetan Shah's appointment as Chairman. Mr Sushil Marfatia will retire from the Board on the conclusion of his term.

The AGM agenda also includes the reappointment of Mr N Sivaraman as Independent Director for a second term of three years from 1 September 2026 to 31 August 2029, and the appointment of Mr Anand Mohan Tiwari as Independent Director for two years effective 31 August 2026. Shareholders will vote on approving related party transactions with holding company Sumitomo Chemical Company, Limited, Japan, aggregating ₹16,235 million for FY 2026-27, representing 50.59% of the Company's consolidated turnover for FY 2025-26.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE258G01013/40cbcddc-9287-468e-ab1f-78690983aac4.pdf

Sumitomo Chemical India Limited filed its Business Responsibility and Sustainability Report for FY26, reporting zero safety incidents and 100% coverage for human rights training. The company disclosed that it achieved a total energy consumption of 403,367 GJ, with 29,797 GJ sourced from renewable energy. The report, which covers the period from 01 April 2025 to 31 March 2026, was assured by M/s Chokshi & Chokshi LLP, Chartered Accountants.

Operational and Employee Metrics

The company operates 5 plants and 7 offices nationally, with a total workforce of 5,155 individuals, including 2,389 employees and 2,766 workers. The report indicates that 100% of permanent employees and workers were covered by health and accident insurance. Sumitomo Chemical India reported that 21.26% of its total turnover was derived from exports during the financial year.

Environmental Performance

Total Scope 1 and Scope 2 greenhouse gas emissions were reported at 23,410 metric tons and 17,149 metric tons of CO2 equivalent, respectively. The company generated 16,075 metric tons of waste, of which 10,572 metric tons were recovered through recycling, reusing, or other recovery operations. Water withdrawal totaled 491,031 kilolitres, with the company implementing zero liquid discharge at its Gajod and Silvassa sites.

Governance and Assurance

Mr Sushil Marfatia, Executive Director, is authorised by the Board as the director responsible for decision-making on sustainability-related issues. The company confirmed that it has not engaged any external agency for the assessment or evaluation of its policies, though internal reviews are conducted regularly. The independent assurance report verified that the identified sustainability information was prepared in all material respects in accordance with the specified criteria.

Stakeholder Engagement and Social Impact

The company identified material issues such as occupational health and safety, consumer health, and human rights as key risks and opportunities. It spent 0.40% of its total revenue on well-being measures for employees and workers. Under its Corporate Social Responsibility initiatives, the company spent ₹123.98 million in designated aspirational districts, benefiting approximately 149,127 individuals.